OncoSec Medical Incorporated announced the appointment of Robert H. Arch, Ph.D. as Chief Executive Officer. Dr. Arch was previously Head of Research at Elpiscience Biopharma Ltd. from October 2019 to June 2021, and Head of the Liver Disease Department at China Novartis Institutes for BioMedical Research from February 2017 to October 2019.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% | 0.00% | 0.00% |
2023 | Motion for Asset Sale Approved for OncoSec Medical Incorporated | CI |
2023 | Motion for Asset Sale Filed by OncoSec Medical Incorporated | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 5 | |
+47.69% | 58.71B | |
-3.44% | 41.31B | |
+36.42% | 39.2B | |
-11.22% | 27.4B | |
+9.13% | 26.55B | |
-22.90% | 18.98B | |
+1.33% | 12.51B | |
+25.32% | 12.08B | |
+21.64% | 11.94B |
- Stock Market
- Equities
- ONCSQ Stock
- News OncoSec Medical Incorporated
- OncoSec Medical Incorporated Appoints Robert H. Arch as Chief Executive Officer